Early detection of breast cancer: New biomarker tests on the horizon?

Molecular Diagnosis and Therapy

Volumn 13, Issue 6, 2009, Pages 349-357

  Jotwani, Aparna C ^a   Gralow, Julie R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOGLUCONOLACTONASE; ALPHA BASIC CRYSTALLIN; ANNEXIN; APTAMER; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CRYSTALLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ESTROGEN; F ACTIN CAPPING PROTEIN SUBUNIT; FIBULIN 2; GLUCONOLACTONASE; GLYCOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MUCIN ASSOCIATED GLYCOPROTEIN; NUCLEIC ACID; OSTEOPONTIN; PLASMA PROTEIN; PROTEIN P53; PROTEIN SUBUNIT; RNA; SOMATOMEDIN; TROPONIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ASPIRATION BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER MODEL; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DNA ADDUCT; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HIGH RISK POPULATION; HUMAN; LAVAGE; MAMMOGRAPHY; MASS SPECTROMETRY; NIPPLE ASPIRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TWO DIMENSIONAL ELECTROPHORESIS; WART VIRUS;

EID: 70450270790     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256340     Document Type: Review

References (60)

1. Etzioni R, Urban N, Ramsey M, et al. The case for early detection. Nat Rev Cancer 2003: 3: 243-252
2. Surveillance Epidemiology and End Results Program, US National Cancer Institute [online]. Available from URL: http://seer.cancer.gov [Accessed 2009 Aug 26]
3. Levenson VV. Biomarkers for early detection of breast cancer: what, when and where? Biochim Biophys Acta 2007; 1770: 847-856
4. Jemal A, Siegal R. Ward E. et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 71-96
5. Khatcheressian JL, Wolff AC. Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 31: 591-597
6. Winer E, Gralow J R. Diller L, et al. Clinical care advances 2008: major research advances in cancer treatment, prevention and screening: a report from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 812-826
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752
8. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; (4): CD001877
9. Humphrey LL, Helfand M, Chan B, et al. Breast cancer screening: a summary of theevidence for the US Preventative Services Task Force. Ann Intern Med 2002; 137: E347-67
10. Wright T, McGechan A. Breast cancer: new technologies for risk assessment and diagnosis. Mol Diagn 2003; 7: 49-55
11. Gralow JR, Ozols RF, Bajorin DF, et al. Clinical care advances 2007: major research advances in cancer treatment, prevention and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313-325
12. Granader EJ, Dwamena B, Carlos RC. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 2008; 15: 1590-1595
13. Breast Cancer Risk Assessment Tool, US National Cancer Institute [online]. Available from URL: http://www.cancer.gov/bcrisktool/ [Accessed 2009 Aug 26]
14. Early Detection Research Network, US National Cancer Institute [online]. Available from URL: http://edrn.nci.nih.gov/ [Accessed 2009 Aug 7]
15. Somiari RI, Somiari S, Russell S, et al. Proteomics of breast carcinoma. J Chromatogr 2005; 815: 215-225
16. Kelly-Spratt KS, Kasarda AE, Igra M, et al. A mouse model for biomarker discovery. J Proteome Res 2008; 7: 3613-3618
17. Debies MT, Gestl SA, Mathers JL, et al. Tumor escape in a Wntl-dependent mouse breast cancer model is enabled by pl9Arf/p53 pathway lesions but not p16lnk4a loss. J Clin Invest 2008; 118: 51-63
18. Whiteaker J R, Zhang H, Zhao L, et al. Integrated pipeline for mass spectometrybased discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007; 6: 3962-3975 (Pubitemid 350032560)
19. Pitteri SJ. Faca VM, Kelly-Spratt KS, et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008; 7: 1481-1489
20. Anderson NL, Anderson NG. The human plasma proteome: history, char- acter, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867
21. Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008; 2 (10-11): 1386-1402
22. Ou K, Yu K, Kesuma D, et al. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res 2008; 7: 1518-1528
23. Vishwanatha JK, Kumble S. Involvement of annexin II in DNA replication: evidence from cell free extracts of Xenopus eggs. J Cell Sci 1993; 105 (Pt 2): 533-540 (Pubitemid 23234172)
24. Moyano JV, Evans JR, Chen F, et al. Alpha-B crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006 Jan: 116(1): 261-270 (Pubitemid 43121811)
25. Gruvberger-Saal SK. Parsons R. Is the small heat shock protein alphaB crystallin an oncogene? J Clin Invest 2006 Jan; 116 (1): 30-32
26. Feuer EJ, Etzioni R, Cronin KA. et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography to PSA testing. Stat Methods Med Res 2004; 13: 421-442 (Pubitemid 39562701)
27. DePotter CR, Beghin C. Praet M M. et al. CEA and HMFG in hyperplastic and malignant lesions of the breast. Pathol Res Pract 1988; 183: 271-276 (Pubitemid 18155869)
28. Taylor-Papadimitriou J. Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002; 7: 209-221
29. Hounsell EF, Young M. Davies MJ. Glycoprotein changes in tumours: a renaissance in clinical applications. Clin Sci (Lond) 1997; 93 (4): 287-293 (Pubitemid 27464290)
30. Reddish MA, Suresh MR, Koganty RR, et al. Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies. Tumour Biol 1998; 19 Suppl. 1:57-66
31. Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res 1996: 140: 101-113
32. Ferreira CSM, Papamichael K, Guilbault G, et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumors. Anal Bioanal Chem 2008; 390: 1039-1050 (Pubitemid 351207802)
33. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037-1041
34. Thomas G, Jacobs KB, Kraft P. et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1pl 1.2 and 14q24.1 (RAD51L1). Nat Genet 2009; 41 (5): 579-584
35. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009; 41 (5): 585-590
36. Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008; 122: 1949-1957
37. Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15:3363-3367
38. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor- associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388-1394
39. Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008 Apr; 7 (4): 1490-1499
40. Regele S, Hohlberger P, Vogl FD, et al. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 1999;81:702-704 (Pubitemid 29458869)
41. Goodell V, Waisman J, Salazar LG, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008; 7: 449-454
42. Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009 Jun 15; 69 (12): 5133-5141
43. Leroy X, Buisine MP, Leteurtre E, et al. MUC1 (EMA): a key molecule of carcinogenesis? Ann Pathol 2006 Sep; 26 (4): 257-266
44. Hermsen BB, Verheijen RH, Menko FH, et al. Humoral immune responses to M UC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007; 43: 1556-1563 (Pubitemid 46891805)
45. Fabian CJ, Kimler BF, Mayo MS, et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005; 12: 185-213 (Pubitemid 40903084)
46. Gong G. DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001; 7: 2410-2414 (Pubitemid 32751643)
47. Sartorius OV, Smith HS, Morris P. et al. Cytologic evaluation of breast fluid in the detection of breast disease. J Natl Cancer Inst 1977; 59: 1073-1080 (Pubitemid 8224271)
48. Wrensch MR. Petrackis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992; 135: 130-141
49. Wrensch MR, Petrakis NL. Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001; 93: 1791-1798 (Pubitemid 33150451)
50. Suijkerbuijk KPM, Van Der Wall E, Vooijs M, et al. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008; 75: 146-152
51. Tice JA, Miike R, Adduci K, et al. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epideiniol Biomarkers Prev 2005; 14: 324-328 (Pubitemid 40270092)
52. Baltzell KA, Moghadassi M, Rice T, et al. Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: a historic prospective study. BMC Cancer 2008;8:75-81
53. Buehring G, Letscher A, McGirr K, et al. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study. Breast Cancer Res Treat 2006; 98: 63-70 (Pubitemid 44050781)
54. Tondre J, Nejad M, Casano A, et al. Technical enhancements to breast ductal lavage. Ann Surg Oncol 2008; 15: 2734-2738
55. Visvanathan K, Santor D, Ali SZ, et al. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer: a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev 2007; 16: 950-955 (Pubitemid 46910097)
56. Lithgow D, Nyamathi A, Elashoff D, et al. C-reactive fluid in nipple aspirate fluid associated with Gail model factors. Biol Res Nurs 2007; 9: 108-116
57. Arun B, Valero V, Logan C, et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 2007; 13: 4943-4948 (Pubitemid 47294803)
58. Cazzaniga M, Gheit T, Casadio C, et al. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat 2009; 114: 599-605
59. Amarante MK, Watanabe MA, et al. The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol 2009; 135 (3): 329-337
60. Mitchell PS, Parkin RK, Kroh EM. et al. Circulating inicroRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518